All Pharma News
price-trendAsk Us
Emalex Releases Results of 12-Month Open-Label Extension Study

Emalex Releases Results of 12-Month Open-Label Extension Study
BUSINESSWIRE
05 Oct 2023
Share Share
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam

Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam
PR NEWSWIRE
01 Mar 2023
Share Share
Emalex Biosciences reports data from Tourette syndrome therapy trial

Emalex Biosciences reports data from Tourette syndrome therapy trial
CLINICAL TRIALS ARENA
12 Jan 2023
Share Share
Emalex Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics

Emalex Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
PR NEWSWIRE
11 Jan 2023
Share Share
Tourette-focused Emalex rakes in $250M series D

Tourette-focused Emalex rakes in $250M series D
Gabrielle Masson FIERCEBIOTECH
03 Nov 2022
Share Share
Emalex Bio Expands CNS Platform to Advance Treatment for Restless Legs Syndrome

Emalex Bio Expands CNS Platform to Advance Treatment for Restless Legs Syndrome
PRNEWSWIRE
01 Mar 2022
Share Share
Emalex Biosciences initiates PII Trial for Childhood-Onset Fluency Disorder

Emalex Biosciences initiates PII Trial for Childhood-Onset Fluency Disorder
PRNEWSWIRE
14 Sep 2021
Share Share
Jeff Aronin`s Emalex raises $35M Series C; British protein degradation

Jeff Aronin`s Emalex raises $35M Series C; British protein degradation
John Carroll ENDPTS
23 Mar 2021
Share Share